FNAM (Evolutionary Genomics) Debt-to-Asset : 1.59 (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics Debt-to-Asset?

Evolutionary Genomics FNAM 31 Debt-to-Asset is 1.59 as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Evolutionary Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Evolutionary Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $3.74 Mil. Evolutionary Genomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $2.35 Mil. Evolutionary Genomics's debt to asset for the quarter that ended in Dec. 2022 was 1.59.

Evolutionary Genomics  (OTCPK:FNAM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Evolutionary Genomics Debt-to-Asset Related Terms

Evolutionary Genomics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Debt-to-Asset Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.56 1.28 1.59

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.07 1.21 1.39 1.59

FNAM vs BXRX, GNCA, XSNX: Debt-to-Asset Comparison

For the Biotechnology subindustry, Evolutionary Genomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Debt-to-Asset falls into.


FNAM
31GF Score
Evolutionary Genomics Inc FNAM
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Evolutionary Genomics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 3.744) / 2.354
=1.59

Evolutionary Genomics's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 3.744) / 2.354
=1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 1.59 mean?
Evolutionary Genomics (FNAM) has a Debt-to-Asset of 1.59 as of Dec. 2022. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Debt-to-Asset too high?
Evolutionary Genomics' current Debt-to-Asset is 1.59. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Debt-to-Asset compare to BXRX and GNCA?
Evolutionary Genomics' Debt-to-Asset of 1.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current Debt-to-Asset is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Debt-to-Asset of 1.59. The current Debt-to-Asset is 1.59. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Debt-to-Asset is 1.59 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price